# Immunochemotherapy for Metastatic Renal Cell Carcinoma

> **NCT00226798** · PHASE2 · UNKNOWN · sponsor: **Rambam Health Care Campus** · enrollment: 45 (—)

## Conditions studied

- Adenocarcinoma Clear Cell

## Interventions

- **DRUG:** Capecitabine (Xeloda)

## Key facts

- **NCT ID:** NCT00226798
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 45 (—)
- **Last updated:** 2006-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226798, "Immunochemotherapy for Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00226798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*